We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
-2.49%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$47.9M
Cap. Flow
-$34.3M
Cap. Flow %
-20.4%
Top 10 Hldgs %
60.49%
Holding
95
New
8
Increased
17
Reduced
13
Closed
10
Avg Time Held
2.2 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.12M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.13M
3
RLMD icon
Relmada Therapeutics
RLMD
+$2.08M
4
ARDX icon
Ardelyx
ARDX
+$1.37M
5
TGTX icon
TG Therapeutics
TGTX
+$1.34M

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$44M
2
CPRX icon
Catalyst Pharmaceutical
CPRX
+$1.64M
3
TECX icon
Tectonic Therapeutic
TECX
+$1.54M
4
TVTX icon
Travere Therapeutics
TVTX
+$1.36M
5
BHVN icon
Biohaven
BHVN
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 53.57%
2 Financials 19.49%
3 Communication Services 15.66%
4 Miscellaneous 8.54%
5 Technology 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ATRC icon
26
AtriCure
ATRC
$2.85B
$1.47M 0.87%
51,400
– –
2025 Q1
4 quarters
ARDX icon
27
Ardelyx
ARDX
$798M
$1.24M 0.74%
+207,000
New +$1.37M
2026 Q1
0 quarters
CLOZ icon
28
Panagram BBB-B CLO ETF
CLOZ
$783M
$1.23M 0.73%
47,807
– –
2023 Q3
10 quarters
JNJ icon
29
Johnson & Johnson
JNJ
$616B
$1.2M 0.72%
4,922
-2,000
-29% -$466K
2021 Q4
17 quarters
RZLT icon
30
Rezolute
RZLT
$346M
$1.13M 0.67%
370,000
+30,000
+9% +$90K
2025 Q3
2 quarters
OBIO icon
31
Orchestra BioMed
OBIO
$328M
$1.08M 0.64%
253,651
+3,651
+1% +$15.5K
2025 Q2
3 quarters
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$10.4B
$1.05M 0.62%
2,000
– –
2025 Q2
3 quarters
VERA icon
33
Vera Therapeutics
VERA
$2.01B
$1.05M 0.62%
26,000
– –
2025 Q1
4 quarters
CNTB icon
34
Connect Biopharma Holdings
CNTB
$57.1M
$1.02M 0.6%
387,835
+187,835
+94% +$490K
2025 Q4
1 quarter
IBB icon
35
iShares Biotechnology ETF
IBB
$10.3B
$929K 0.55%
5,500
– –
2025 Q2
3 quarters
PFE icon
36
Pfizer
PFE
$169B
$908K 0.54%
32,337
– –
2021 Q4
17 quarters
BMY icon
37
Bristol-Myers Squibb
BMY
$122B
$826K 0.49%
13,622
-8,378
-38% -$488K
2025 Q1
4 quarters
CNQ icon
38
Canadian Natural Resources
CNQ
$111B
$819K 0.49%
16,800
– –
2021 Q4
17 quarters
BIIB icon
39
Biogen
BIIB
$34.4B
$733K 0.44%
4,000
-2,000
-33% -$369K
2025 Q3
2 quarters
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$1.43B
$693K 0.41%
33,069
+13,063
+65% +$294K
2025 Q1
4 quarters
AAPL icon
41
Apple
AAPL
$5.01T
$633K 0.38%
2,494
– –
2021 Q4
17 quarters
MSFT icon
42
Microsoft
MSFT
$3.93T
$592K 0.35%
1,600
– –
2021 Q4
17 quarters
VSTM icon
43
Verastem
VSTM
$783M
$551K 0.33%
+104,000
New +$641K
2026 Q1
0 quarters
ADMA icon
44
ADMA Biologics
ADMA
$2.39B
$542K 0.32%
60,200
– –
2025 Q4
1 quarter
IBM icon
45
IBM
IBM
$219B
$519K 0.31%
2,142
– –
2023 Q1
12 quarters
PTHS icon
46
Pelthos Therapeutics
PTHS
$77.1M
$443K 0.26%
21,073
+1,792
+9% +$42.5K
2025 Q3
2 quarters
KURA icon
47
Kura Oncology
KURA
$808M
$429K 0.26%
52,767
+13,558
+35% +$116K
2025 Q3
2 quarters
EOLS icon
48
Evolus
EOLS
$469M
$408K 0.24%
99,338
– –
2025 Q4
1 quarter
CGEM icon
49
Cullinan Oncology
CGEM
$832M
$344K 0.2%
+24,200
New +$311K
2026 Q1
0 quarters
SLDB icon
50
Solid Biosciences
SLDB
$593M
$339K 0.2%
47,143
-115,297
-71% -$741K
2025 Q1
4 quarters
1
2
3 4

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q1 2026 Portfolio in Review

As of Q1 2026, David M. Knott Jr held 95 positions worth $168M, down 22% from $216M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

David M. Knott Jr withdrew a net $34.3M in Q1 2026, closing 10 positions and reducing 13 holdings. Its most notable exit was Calumet Specialty Products, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 41% a quarter earlier, followed by Financials and Communication Services.

Against the trend, David M. Knott Jr opened a new position in Iovance Biotherapeutics worth $5.62M.

  • David M. Knott Jr's largest Q1 2026 buy was Iovance Biotherapeutics: 1,600,000 shares worth $5.62M.
  • David M. Knott Jr added most to Agios Pharmaceuticals in Q1 2026, an estimated $2.13M increase.
  • David M. Knott Jr's biggest Q1 2026 reduction was Catalyst Pharmaceutical, cutting an estimated $1.64M.
  • David M. Knott Jr fully exited Calumet Specialty Products in Q1 2026, selling an estimated $44M.
  • David M. Knott Jr's ten largest holdings make up 60% of its $168M portfolio in Q1 2026.
  • David M. Knott Jr opened 8 new positions and closed 10 in Q1 2026.
  • David M. Knott Jr's portfolio value fell 22% quarter-over-quarter to $168M.

Based on David M. Knott Jr's 13F filing for Q1 2026, filed 14 May 2026.